1. Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment. Issue 2 (28th December 2022) Authors: Genge, Angela; Pattee, Gary L.; Sobue, Gen; Aoki, Masashi; Yoshino, Hiide; Couratier, Philippe; Lunetta, Christian; Petri, Susanne; Selness, Daniel; Bidani, Sachin; Hirai, Manabu; Sakata, Takeshi; Salah, Alejandro; Apple, Stephen; Wamil, Art; Kalin, Alexander; Jackson, Carlayne E. Journal: Muscle & nerve Issue: Volume 67:Issue 2(2023) Page Start: 124 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗